Lipocine (NASDAQ: LPCN) reported Q2 EPS of ($0.32), $0.12 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $190 million versus the consensus estimate of $162.5 thousand.

For earnings history and earnings-related data on Lipocine (LPCN) click here.